Eyegate Pharmaceuticals (NASDAQ:EYEG) received a $5.00 price target from investment analysts at HC Wainwright in a note issued to investors on Tuesday, December 19th. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 284.62% from the stock’s current price.
Eyegate Pharmaceuticals (NASDAQ EYEG) traded up $0.06 during trading hours on Tuesday, hitting $1.30. 723,074 shares of the stock traded hands, compared to its average volume of 389,101. Eyegate Pharmaceuticals has a one year low of $0.90 and a one year high of $3.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $22.37 and a price-to-earnings ratio of -1.11.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned approximately 2.01% of Eyegate Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 11.94% of the company’s stock.
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.